Clinical trials: Cytomegalovirus
DNA Virus Infection, Herpesviridae Infections
Prophylaxis With Ganciclovir Improves Graft Survival in Renal Allograft Recipients
Study Phase: IV Study Type: Open-label, multicenter, randomised clinical trial with two arms stratified for an intensified immunosuppressive regimen in patients at high risk for acute rejection.
- Conditions
- DNA Virus Infection, Herpesviridae Infections, Cytomegalovirus Infection
- Trial name
- NCT00373165
- Testing
- Ganciclovir
- Volunteers
- 150 people
- Sponsor
- Lower Saxony Center for Nephrology
COVID-19, Cytomegalovirus (CMV), Tocilizumab, Anakinra, Mortality
The Relationship Between CMV* Reactivation and Anti-cytokine Treatment in Critical COVID-19 Patients
The risk of secondary infection is high in critical patients hospitalized with the diagnosis of COVID-19. Immunosuppressive treatments are commonly used in critical COVID-19 patients, and immune dysfunction and CMV reactivation…
- Trial name
- Cytomegalovir (NCT05419206)
- Testing
- CMV DNA analysis
- Where
- Turkey (Türkiye)
- Volunteers
- 167 people
- Sponsor
- Ramazan Gozukucuk
Precancerous/Nonmalignant Condition
Cytomegalovirus Vaccine in Healthy Participants
RATIONALE: Vaccines may help the body build an effective immune response against cytomegalovirus. PURPOSE: This randomized phase I trial is studying the side effects and best dose of cytomegalovirus vaccine in healthy…
- Trial name
- NCT00712634
- Testing
- CMVpp65-A*0201 peptide vaccine
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Transplantation Infection, Cytomegalovirus Infection
Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine A
Cytomegalovirus (CMV) infection is the most frequent opportunistic viral infection after transplantation. It is associated with an increased incidence of acute rejection and lower graft and patient survivals.
- Trial name
- EVERCMV (NCT02328963)
- Testing
- Everolimus, mycophenolic acid
- Where
- 9 sites in France
- Volunteers
- 186 people
- Sponsor
- University Hospital, Bordeaux
Adenovirus Infection, Epstein-Barr Virus Infections
Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE)
Patient's on this protocol have a type of blood cell cancer, other blood disease or a genetic disease and have received a stem cell transplant.
- Conditions
- Adenovirus Infection, Epstein-Barr Virus Infections, Cytomegalovirus Infections, Stem Cell Transplant
- Trial name
- NCT01070797
- Testing
- Multi-virus Specific T cells
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Baylor College of Medicine
Pregnant Women Undergoing TOP, TOP - Failed Attempted Termination of Pregnancy
Prenatal Treatment of Congenital Cytomegalovirus Infection With Letermovir Randomized Against Valaciclovir - CYMEVALIII STEP1
In the model of the perfused cotyledon, Letermovir crosses the placenta to reach appropriate fetal concentration. The cotyledon model can only be performed in the third trimester placenta.
- Trial name
- CYMEVAL3-STEP1 (NCT04732260)
- Testing
- Letermovir
- Where
- France
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
CMV
Prophylaxis of Cytomegalovirus Infection With Adoptive Cell Inmunotherapy
Cytomegalovirus (CMV) infection is a major cause of morbidity and mortality for recipients of allogeneic hematopoietic stem cell transplantation(HSCT).
- Trial name
- INMUNOCELL (NCT04056533)
- Testing
- CMV CTLs
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- Instituto de Investigación Marqués de Valdecilla
Ovarian Cancer, Fallopian Tube Cancer
The Role of Cytomegalovirus and Inflammation on Patient Symptoms and Outcomes in Ovarian Cancer
Cytomegalovirus (CMV), a widely prevalent virus in the general US population, has been shown to be associated with increased inflammation and mortality.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- NCT03921658
- Where
- United States
- Volunteers
- 255 people
- Sponsor
- University of Minnesota
Cytomegalovirus Infections, Primary Immune Deficiency Disorder
Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)
CMV cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolescents and young adults (CAYA) with refractory cytomegalovirus (CMV) infection post…
- Trial name
- NCT03266640
- Testing
- viral specific cytotoxic t-lymphocytes
- Where
- 9 sites in United States
- Volunteers
- 20 people
- Sponsor
- New York Medical College
CMV Infection
Cytomegalovirus Infection After HSCT and PT-CY as GVHD Prophylaxis >> GVHD PROPHYLAXIS ERA
Multicentre, observational, retrospective study to analyze the differences in CMVi pattern and recurrences between two groups of allogeneic HSCT patients (haplo vs no haplo HSCT), with intervention both postransplant…
- Trial name
- CY-CMV-2020 (NCT05315882)
- Where
- Spain
- Volunteers
- 300 people
- Sponsor
- Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
BKV Infection, EBV Infection
Evaluation of the Safety and Efficacy of LB-DTK-MV in Patients Diagnosed With Antiviral-Resistant CMV, BKV, or EBV Infection or Associated Diseases Following Anticancer Therapy or Allogeneic Hematopoietic Stem Cell Transplantation.
The goal of this clinical trial is to evaluate the efficacy and safety of Multi-Virus Specific T cells (LB-DTK-MV) to treat patients diagnosed with antiviral-resistant CMV, BKV, or EBV infection or associated diseases after…
- Conditions
- BKV Infection, EBV Infection, CMV Infection
- Trial name
- NCT07670468
- Testing
- LB-DTK-MV
- Where
- South Korea
- Volunteers
- 27 people
- Sponsor
- LucasBio
Cytomegalovirus (CMV)
A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell Transplants
This study is about treatment options for cytomegalovirus infections in people who have received stem cell transplants. The main aim of the study is to check if the cytomegalovirus infection can no longer be detected after…
- Trial name
- NCT02927067
- Testing
- Maribavir, Valganciclovir
- Where
- 129 sites in United States, Australia and 21 more
- Volunteers
- 553 people
- Sponsor
- Shire
Cytomegalovirus Infections, Hematopoietic Stem Cell Transplantation (HSCT)
CMV-CMI in csCMVi After HSCT
Cytomegalovirus (CMV) reactivation is a common and serious complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT), and the reconstitution of CMV-specific cell-mediated immunity (CMV-CMI) plays a key…
- Conditions
- Cytomegalovirus Infections, Hematopoietic Stem Cell Transplantation (HSCT), Immune Reconstitution
- Trial name
- NCT07688759
- Testing
- Anti-Cytomegalovirus Therapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Cytomegalovirus Infection
Valganciclovir for Treatment of Cytomegalovirus Infection in Solid Organ Transplant Patients
The objectives of this study were: 1. To demonstrate the efficacy/safety of a short therapeutic strategy of treatment of CMV infection/disease in SOT patients (kidney, liver and heart recipients) based on 21 days of treatment. 2.
- Trial name
- NCT00730769
- Testing
- Single arm (ganciclovir and valganciclovir)
- Where
- Spain
- Volunteers
- 21 people
- Sponsor
- Salvador Gil-Vernet
Cytomegalovirus Infections, Heart Transplantation
A Study on the Pharmacokinetics and Safety of Valcyte (Valganciclovir) in Pediatric Heart Transplant Recipients Less Than 4 Months of Age
This open label study will assess the pharmacokinetics and the safety and tolerability of Valcyte (valganciclovir) powder for oral solution in neonatal and infant heart transplant patients < 4 months of age.
- Trial name
- NCT01165580
- Testing
- valganciclovir [Valcyte]
- Where
- 19 sites in United States, Canada and 1 more
- Volunteers
- 17 people
- Sponsor
- Hoffmann-La Roche
Cytomegalovirus Infection
Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant Recipients
This was a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study of brincidofovir (BCV) administered orally once or twice weekly for up to 11 weeks.
- Trial name
- NCT00942305
- Testing
- Brincidofovir
- Where
- 26 sites in United States
- Volunteers
- 239 people
- Sponsor
- Jazz Pharmaceuticals
Cytomegalovirus Infections
Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation
The study evaluated the efficacy and safety of a prolonged, continuous course of Valganciclovir (Valgan) in the prevention of CMV by comparing 3 months of Vaglanciclovir, the standard of care upon initiation of the study, to 12…
- Trial name
- Valgan (NCT00227370)
- Testing
- valganciclovir
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Duke University
Cytomegalovirus (CMV)
A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections
The main aim of this study is to learn how safe maribavir is in Chinese adults who have undergone hematopoietic stem cell or organ transplantation and have a cytomegalovirus (CMV) infection and how well they tolerate treatment…
- Trial name
- NCT06439342
- Testing
- Maribavir
- Where
- 11 sites in China
- Volunteers
- 20 people
- Sponsor
- Takeda
Viral Infection
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
The purpose of this study is to use VSTs (virus-specific T cells) from a donor that is a partial HLA (human leukocyte antigen) match with the patient to treat viral infections after an allogeneic hematopoietic stem cell…
- Trial name
- TETRAVI (NCT04013802)
- Testing
- HLA-matched VSTs
- Where
- 2 sites in United States
- Volunteers
- 47 people
- Sponsor
- Baylor College of Medicine
Cytomegalovirus Infections
VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients
This 2 arm study will evaluate the efficacy and safety of oral Valcyte compared with intravenous ganciclovir for the treatment of CMV disease in solid organ transplant recipients.
- Trial name
- NCT00431353
- Testing
- Ganciclovir, valganciclovir [Valcyte]
- Where
- 50 sites in Australia, Austria and 19 more
- Volunteers
- 325 people
- Sponsor
- Hoffmann-La Roche